Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Case Rep Oncol. 2011 Sep;4(3):531-3. doi: 10.1159/000334581. Epub 2011 Nov 11.

Addition of bevacizumab to temsirolimus in kidney cancer patients.

Author information

  • 1Centre Léon Bérard, Department of Medical Oncology, Lyon, France.

Abstract

Treatment of metastatic kidney cancer has changed dramatically in the past years with the use of VEGF-targeted therapies and mTOR inhibitors. However, resistance occurs. We report here two cases of patients who benefited, both on disease control and side effects, from the addition of bevacizumab to temsirolimus, after progression on the mTOR inhibitor alone.

KEYWORDS:

Bevacizumab; Combination; Renal carcinoma; Temsirolimus; Treatment

PMID:
22171218
[PubMed]
PMCID:
PMC3237108
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for S. Karger AG, Basel, Switzerland Icon for PubMed Central
    Loading ...
    Write to the Help Desk